How to Follow, Manage and Treat Cardiac Dysfunction in Patients With Her2+ Breast Cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Cardiac remodelling and dysfunction in cancer patients receiving cardiotoxic therapies: proteomic and metabolomic profiling.European heart journal · 2026
   Article
2. Therapeutic Implications of ErbB Pathway Modification in Heart Failure with Reduced Ejection Fraction.JACC. Basic to translational science · 2025
   Article
3. HER-SAFE study design: an open-label, randomised controlled trial to investigate the safety of withdrawal of pharmacological treatment for recovered HER2-targeted therapy-related cardiac dysfunction.BMJ open · 2025
   Article
4. Cardiovascular Considerations After Cancer Therapy: Gaps in Evidence andJACC. CardioOncology · 2025
   Review
5. Cancer therapy-related cardiac dysfunction and the role of cardiovascular imaging: systemic review and opinion paper from the Working Group on Cardio-Oncology of the Korean Society of Cardiology.Journal of cardiovascular imaging · 2024
   Review
6. Cardiovascular Concerns, Cancer Treatment, and Biological and Chronological Aging in Cancer:JACC. CardioOncology · 2024
   Review
7. Cardiovascular toxicities of chemotherapies: challenging the paradigm for left ventricular ejection fraction monitoring during and after treatment.American heart journal plus : cardiology research and practice · 2022
   Article
8. How to Treat Breast Cancer After Childhood Cancer: Management of Oncologic and Cardiovascular Concerns.JACC. CardioOncology · 2022
   Review
9. Driven by Impact, Not Impact Factor.JACC. CardioOncology · 2021
   Article
10. Heart Failure With Targeted Cancer Therapies: Mechanisms and Cardioprotection.Circulation research · 2021
    Review
11. Potential Influence of Duchenne Muscular Dystrophy Carrier on Breast Cancer Treatment-Related Cardiomyopathy: A Case Report.Case reports in oncology
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as